ATS 2026
Targeting TNF-α to Preserve Lung Function in Pulmonary Sarcoidosis: Results from a Phase 1b/2a Multiple-Ascending-Dose Trial of XTMAB-16
Abstract: P1992
Session: Lake Breaking Abstract
Poster available: Sunday, May 17, 2026, 11:30 AM – 1:15 PM
Xentria presents an update on its lead investigational therapy, XTMAB-16, at the 2026 ATS International Conference. Xentria provided an overview of XTMAB-16’s dose-ranging study. XTMAB-16 demonstrated a favorable safety and tolerability profile in patients with pulmonary sarcoidosis. These findings support Xentria’s continued clinical development and dose selection for further evaluation.
Key points from the poster include:
- XTMAB-16 was well tolerated across multiple dose regimens in pulmonary sarcoidosis, with a safety profile consistent with the established class effects of TNFα inhibitors and no unexpected safety signals1
- Investigational treatment demonstrated exploratory signals of corticosteroid reduction, maintenance of lung function and on-target TNFα blockade.
- Integrated safety, PK/PD, biomarker and clinical data from Part A support selection of 4mg/kg Q4W for continued clinical evaluation.
Conclusions from the poster include:
- XTMAB-16 shows an acceptable safety profile and early efficacy signals in pulmonary sarcoidosis, supporting continued development and advancement of the 4mg/kg Q4W regimen for further evaluation.
About XTMAB-16
XTMAB-16 is novel biologic developed by Xentria to address the unmet medical need for patients with sarcoidosis, a rare inflammatory disease that affects multiple organs in the body. XTMAB-16 is a monoclonal antibody designed to suppress the inflammatory pathways promotion of sarcoidosis granuloma formation. No TNF-α inhibitor is currently approved for the treatment of sarcoidosis. Extensive analyses have been conducted to demonstrate the physio-chemical properties and pharmacology of XTMAB-16 as a TNFα inhibitor. The clinical study of this effect remains ongoing.
XTMAB-16 is not available for sale in the United States. Future commercial use will depend on successful clinical trials and regulatory review and approval.
About Sarcoidosis
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of noncaseating epithelioid granulomas, accompanied by infiltration of mononuclear cells and destruction of microarchitecture. The disease can affect the skin, eyes, heart, and central nervous system, and >90% of cases involve the lungs. While medications for systemic organ involvement often control this disease, some patients fail to respond to initial treatments and require additional targeted therapy, resulting in significant costs and treatment burdens. This disease presents a significant unmet medical need and a very important area of research and development for Xentria.
Reference
1. Offman, E., et al. “Leveraging in Vitro and Pharmacokinetic Models to Support Bench to Bedside Investigation of XTMAB-16 as a Novel Pulmonary Sarcoidosis Treatment.” Frontiers in Pharmacology, vol. 14, 2023, article 1066454.
American Thoracic Society (ATS)
International Conference 2026
Date: May 15-20, 2026
Location: Orlando
Presentation: Abstract poster